Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biological therapies for atopic dermatitis: An update�(Review)
Diana Deleanu, Irena Nedelea
Experimental and Therapeutic Medicine (2018)
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
Emma Guttman‐Yassky, Andrew Blauvelt, Lawrence F. Eichenfield, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 4, pp. 411-411
Open Access | Times Cited: 278
A basophil-neuronal axis promotes itch
Fang Wang, Anna M. Trier, Fengxian Li, et al.
Cell (2021) Vol. 184, Iss. 2, pp. 422-440.e17
Open Access | Times Cited: 183
JAK inhibitors and infections risk: focus on herpes zoster
Flavia Sunzini, Iain B. McInnes, Stefan Siebert
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 101
Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis
Hidaya A. Kader, Muhammad Azeem, Suhib A. Jwayed, et al.
Cells (2021) Vol. 10, Iss. 6, pp. 1392-1392
Open Access | Times Cited: 66
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
El‐Bdaoui Haddad, Sonya Cyr, Kazuhiko Arima, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 7, pp. 1501-1533
Open Access | Times Cited: 45
Recent advances and future prospective of topical and transdermal delivery systems
Pronalis Tapfumaneyi, Mohammad Imran, Yousuf Mohammed, et al.
Frontiers in Drug Delivery (2022) Vol. 2
Open Access | Times Cited: 39
Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases
Brittany A. Martínez, Sneha Shrotri, Kathryn M. Kingsmore, et al.
Science Advances (2022) Vol. 8, Iss. 17
Open Access | Times Cited: 33
Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues
Elisa Molinelli, Edoardo De Simoni, Matteo Candelora, et al.
Antibiotics (2023) Vol. 12, Iss. 6, pp. 978-978
Open Access | Times Cited: 21
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
Barbara Rewerska, Lawrence Sher, Sady Alpizar, et al.
Journal of Allergy and Clinical Immunology Global (2023) Vol. 3, Iss. 1, pp. 100195-100195
Open Access | Times Cited: 20
TSLP as druggable target – a silver-lining for atopic diseases?
Partho P. Adhikary, Zheng Tan, Brent D. G. Page, et al.
Pharmacology & Therapeutics (2020) Vol. 217, pp. 107648-107648
Closed Access | Times Cited: 46
Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT)
Suzete Costa, João Pedro Aguiar, Mónica Duarte Oliveira, et al.
Expert Review of Clinical Immunology (2025)
Closed Access
Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases
Hanlin Zhang, Jia Zhou, Keyun Tang, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Novel drug delivery systems in topical treatment of atopic dermatitis
Meghna Dabhadkar, Madhur Kulkarni
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Trends in nanoformulations for atopic dermatitis treatment
Estefânia Vangelie Ramos Campos, Patrícia Luiza de Freitas Proença, Lorena Doretto-Silva, et al.
Expert Opinion on Drug Delivery (2020) Vol. 17, Iss. 11, pp. 1615-1630
Closed Access | Times Cited: 32
Selective IL-13 inhibitors for the treatment of atopic dermatitis
Francisca Gonçalves, Egídio Freitas, Tiago Torres
Drugs in Context (2021) Vol. 10, pp. 1-17
Open Access | Times Cited: 26
Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment
Caitlin Thomas, Afaf Raibouaa, Andreas Wollenberg, et al.
BMJ Open (2022) Vol. 12, Iss. 8, pp. e058799-e058799
Open Access | Times Cited: 16
IL-4Rα signalling in B cells and T cells play differential roles in acute and chronic atopic dermatitis
Martyna Scibiorek, Nontobeko Mthembu, Sandisiwe Mangali, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 10
The Pathology of Type 2 Inflammation-Associated Itch in Atopic Dermatitis
Catharina Sagita Moniaga, Mitsutoshi Tominaga, Kenji Takamori
Diagnostics (2021) Vol. 11, Iss. 11, pp. 2090-2090
Open Access | Times Cited: 22
Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation
Chris M. Li, Zhibin Chen
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 21
In Vitro Skin Retention of Crisaborole after Topical Application
Adriana Fantini, Anna Demurtas, Sara Nicoli, et al.
Pharmaceutics (2020) Vol. 12, Iss. 6, pp. 491-491
Open Access | Times Cited: 22
Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis
S. K. Uppal, Donovan G. Kearns, Vipawee S. Chat, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 2, pp. 626-636
Closed Access | Times Cited: 22
Extent and Impact of Inadequate Disease Control in US Adults with a History of Moderate to Severe Atopic Dermatitis Following Introduction of New Treatments
Andreas Westh Vilsbøll, Peter Anderson, James Piercy, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 2, pp. 475-486
Open Access | Times Cited: 20
Tralokinumab for the Treatment of Atopic Dermatitis
Egídio Freitas, Emma Guttman‐Yassky, Tiago Torres
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 5, pp. 625-638
Closed Access | Times Cited: 18
Combined application of dupilumab and mite allergen-specific immunotherapy in children with moderate to severe atopic dermatitis
Bo Ding, Yin Hwa Lai, Yanming Lu
Allergologia et Immunopathologia (2023) Vol. 51, Iss. 2, pp. 184-190
Open Access | Times Cited: 7
MicroRNA‑146a as a potential regulator involved in the pathogenesis of atopic dermatitis
Fenggen Yan, Weiwei Meng, Siqi Ye, et al.
Molecular Medicine Reports (2019)
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top